Song Chao, Feng Yanli, Ge Fanmei, Zhang Zhiyun, Su Baoxiong
Hematology Department, Affiliated Hospital of Yan'an University No. 43 Zhongxin Street, Baota District, Yan'an 716000, Shaanxi Province, China.
Hematology Department, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine No. 5 Weiyang West Road, Qindu District, Xianyang 712000, Shaanxi Province, China.
Am J Transl Res. 2022 Sep 15;14(9):6313-6322. eCollection 2022.
To evaluate the efficacy of rituximab combined with GDP regimen (gemcitabine + cisplatin + dexamethasone) in the treatment of non-Hodgkin lymphoma and its impact on the immune function of patients.
Clinical data of 88 patients with non-Hodgkin lymphoma (NHL) treated in Affiliated Hospital of Yan'an University from February 2017 to February 2019 were analyzed retrospectively. Among them, 40 patients treated with the second-line regimen (gemcitabine + cisplatin + dexamethasone) were served as the control group, and 48 patients received additional rituximab were as the observation group. The therapeutic effect, incidence of adverse reactions, levels of complement (C3, C4) and immunoglobulin [immunoglobulin (Ig) G, IgM, IgA] before and after treatment were compared between the two groups. Cox regression analysis was used to analyze the prognostic factors of patients.
The total response rate of patients in observation group was higher than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions (hair loss, nausea and vomiting, thrombocytopenia, anemia and bone marrow suppression) between the two groups (P>0.05). After treatment, the levels of C3 and C4 in both groups were lower than those before treatment, and the decrease in observation group were more evident than that in control group (P<0.05). No notable fluctuation was observed in the levels of IgG, IgM and IgA in both groups between before and after treatment (P>0.05). Cox regression analysis found that Ann Arbor stage and pretreatment disease status were the factors affecting the prognosis of patients.
Rituximab combined with GDP regimen has a significant effect on the treatment of non-Hodgkin lymphoma, and Ann Arbor stage and pretreatment disease state are prognostic factors for patients with NHL.
评估利妥昔单抗联合GDP方案（吉西他滨+顺铂+地塞米松）治疗非霍奇金淋巴瘤的疗效及其对患者免疫功能的影响。
回顾性分析2017年2月至2019年2月在延安大学附属医院接受治疗的88例非霍奇金淋巴瘤（NHL）患者的临床资料。其中，40例接受二线方案（吉西他滨+顺铂+地塞米松）治疗的患者作为对照组，48例额外接受利妥昔单抗治疗的患者作为观察组。比较两组患者的治疗效果、不良反应发生率、治疗前后补体（C3、C4）水平和免疫球蛋白[免疫球蛋白（Ig）G、IgM、IgA]水平。采用Cox回归分析患者的预后因素。
观察组患者的总缓解率高于对照组（P<0.05）。两组患者不良反应（脱发、恶心呕吐、血小板减少、贫血和骨髓抑制）的发生率无显著差异（P>0.05）。治疗后，两组患者的C3和C4水平均低于治疗前，且观察组的下降更为明显（P<0.05）。两组患者治疗前后IgG、IgM和IgA水平均未观察到明显波动（P>0.05）。Cox回归分析发现，Ann Arbor分期和治疗前疾病状态是影响患者预后的因素。
利妥昔单抗联合GDP方案治疗非霍奇金淋巴瘤疗效显著，Ann Arbor分期和治疗前疾病状态是NHL患者的预后因素。
